Boldenone 250

• Brand: Magnus Pharmaceuticals
• Content: 10 ml Vial | 250 mg/ml
• Manufactured in Europe

Product Overview

Boldenone 250 delivers Boldenone Undecylenate, a long-acting -testosterone derivative valued for lean muscle growth, sustained strength adaptation, and erythropoietic research.

Each 10 ml vial provides 2,500 mg total active compound (250 mg/ml 10 ml) in GMP-aligned, sterile glass ampoules, stable for 36 months.

Its ~14-day half-life reduces dosing frequency, making it ideal for long-term muscle growth, nitrogen balance, and endurance studies.

Key Research Highlights

Exact potency: 250 mg/ml for accurate dose–response replication

Extended depot activity: ~14-day half-life supports reduced handling frequency

Anabolic benefits: Promotes fat-free mass, feed efficiency, and muscle fiber growth in research models

Erythropoietic effect: Elevates hemoglobin and red-cell indices, aiding anemia and endurance investigations

Sterile GMP packaging: Ensures long-term sample integrity

Suggested Laboratory Applications

Lean muscle growth and nitrogen retention research

Endurance and oxygen-carrying capacity studies

Comparative analysis with testosterone derivatives

Long-term anabolic hormone and performance-adaptation protocols

Technical Specifications

PubChem-Supported Research Insights

Promotes lean muscle mass and protein synthesis in lab and livestock models

Improves feed efficiency and strength markers in research studies

Stimulates erythropoiesis, enhancing oxygen delivery and endurance potential

Documented Research Side Effects

(In vivo & literature references)

Hepatic and renal strain at high or prolonged dosing

Potential cardiovascular and immune effects in sensitive models

Androgenic effects: Acne, voice deepening, lipid alterations

Positive anti-doping test due to long-lived metabolites

Handling & Compliance

For Research Use Only – Not for human or veterinary use

Store at 15–25°C, away from direct light

Follow SDS (Safety Data Sheet) for safe handling and disposal

Purchase confirms qualified researcher status